NGS revenue guidance was raised to $205 million to $209 million, reflecting 21%-24% growth. Biopharma revenue was guided to $23 million for fiscal 2025, representing 13% year-over-year growth.

Despite Reddit's strong fundamentals and network effects, valuation appears 50% too high. Learn why RDDT stock is a Sell.

More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...

The European Commission has published on the 29th January the “Competitiveness Compass for the EU”, setting out ambitious initiatives aimed ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Bio-Plastic Market. The global bio-plastic market is witnessing a remarkable transformation as industries and consumers ...

This tobacco company offers value investors a great entry point and a rich 7.84% dividend. Altria Group Inc. (NYSE: MO) ...

The global 3D bio-printing market is set for extraordinary growth ... statistical data models for pricing analysis, ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...